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Abstract
Background: To gain a better understanding of the effects of therapeutic agents on the tumor
microenvironment in invasive cancers, we developed a co-culture model from an invasive lobular
carcinoma. Tumor cells expressing HER2/neu organize in nests surrounded by alpha-Smooth
Muscle Actin (α-SMA) expressing tumor stroma to resemble the morphology of an invading tumor.
This co-culture, Mammary Adenocarcinoma Model (MAM-1) maintains a 1:1 ratio of HER2/neu
positive tumor cells to α-SMA-reactive stromal cells and renews this configuration for over 20
passages in vitro.
Methods: We characterized the cellular elements of the MAM-1 model by microarray analysis,
and immunocytochemistry. We developed flow cytometric assays to evaluate the relative
responses of the tumor and stroma to the tyrosine kinase inhibitor, Iressa.
Results: The MAM-1 gene expression profile contains clusters that represent the ErbB-2 breast
cancer signature and stroma-specific clusters associated with invasive breast cancers. The stability
of this model and the ability to antigenically label the tumor and stromal fractions allowed us to
determine the specificity of Iressa, a receptor tyrosine kinase inhibitor, for targeting the tumor cell
population. Treatment resulted in a selective dose-dependent reduction in phospho-pMEK1/2 and
pp44/42MAPK in tumor cells. Within 24 h the tumor cell fraction was reduced 1.9-fold while the
stromal cell fraction increased >3-fold, consistent with specific reductions in phospho-pp44/42
MAPK, MEK1/2 and PCNA in tumor cells and reciprocal increases in the stromal cells. Erosion of
the tumor cell nests and augmented growth of the stromal cells resembled a fibrotic response.
Conclusion: This model demonstrates the specificity of Iressa for HER2/neu expressing tumor
cells versus the tumor associated myofibroblasts and is appropriate for delineating effects of
therapy on signal transduction in the breast tumor microenvironment and improving strategies that
can dually or differentially target the tumor and stromal elements in the microenvironment.
Background
The development of targeted therapies for the specific
inactivation of receptor tyrosine kinase oncogenes
involved in tumor initiation and progression has lead to
the ability to target signal transduction as a modality for
cancer treatment and prevention [1,2]. ZD1839 (gefitinib,
Iressa®), an orally active, selective EGFR-Tyrosine Kinase
Inhibitor (TKI) that blocks signal transduction pathways
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implicated in proliferation and survival of cancer cells and
other host-dependent processes that promote cancer
growth [3,4]. To date, we have already demonstrated the
efficacy of Iressa against mammary and salivary gland
tumor cell lines derived from transgenic mice that over-
express the activated rat HER2/neu [5,6]. These studies
focused mainly on the direct effects of Iressa on tumor
cells. More recently, we have determined that Iressa can
also prevent the outgrowth and progression of mammary
and salivary gland cancers from early hyperplasias [7].
During these studies, we observed significant changes in
the microenvironment as a result of treatment. It has been
widely recognized that the tumor microenvironment
plays a major role in dictating tumor behavior and pro-
gression as well as response to therapy. To better define,
characterize and understand the effects of Iressa on the
tumor and its microenvironment we developed a stable
model of HER2/neu positive mammary tumor cells in co-
culture with alpha-Smooth Muscle Actin (α-SMA)-posi-
tive stromal cells that recapitulate the microenvironment
of an invasive carcinoma.
Several organotypic breast cancer models and co-cultures
have been described. These include admixtures of tumor
cells and fibroblasts or stromal cells [8-10], mammary
tumor cells grown as spheroids [11] or 3-dimensional
scaffolds [12], organ cultures [13] and orientated lumen
forming acinar cultures [14,15]. These can be laborious to
maintain and difficult to analyze without specialized rea-
gents and equipment. We have developed a self-renewing
model that circumvents some of these technical barriers
and has proven to be stable, reliable and user friendly. We
have identified several advantages to the Mammary Aden-
ocarcinoma Model (MAM-1) for screening preventive and
therapeutic agents, emphasizing the need to evaluate ther-
apies in the context of homotypic microenvironment.
MAM-1 is immortal and faithfully recapitulates the mor-
phology of invasive carcinomas that arise in BALB-NeuT
transgenic mice, a model for HER2/neu driven lobular
carcinoma [16]. MAM-1 grows rapidly in vitro and in vivo
and maintains a 1:1 tumor-to-stroma ratio with routine
passaging. This ratio can be manipulated with differential
trypsinizations. This configuration is stable for over 20
passages. In MAM-1 there is no need for separate cultures,
special media or culture conditions. MAM-1 can be used
to test any agent or type of therapy, especially HER2 and
stroma targeted therapies including biological and immu-
notherapies. Using MAM-1 treatment effects can be fol-
lowed by out growth assays in vitro and in vivo (residual
tumorigenic potential) in BALB/c mice. A key advantage
to MAM-1 is the ability to simultaneously evaluate tumor
cells and stromal cells using convenient markers (i.e., α-
SMA, HER2) that are stable and suitable for flow cytome-
try (FACs) and immunofluorescent imaging. Further-
more, cells can be fractioned, based on these stable
markers, to generate lysates for IP, Western blot, and mul-
tiplex bead arrays or generate RNA and DNA for microar-
ray and methylation analyses. Finally, MAM-1 is suitable
for use in assays that evaluate invasive and angiogenic
potential of cells.
In this paper we describe the development of the MAM-1
co-culture model and methods for manipulating and ana-
lyzing it to evaluate mechanism(s) of the receptor tyrosine
kinase inhibitor, Iressa. We further resolve a dynamic rec-
iprocity between tumor and stromal cell populations dur-
ing growth and treatment.
Methods
BALB-NeuT Transgenic animals
Two stock BALB-NeuT transgenic males were obtained
through collaboration with Dr. Guido Forni. The BALB-
NeuT strain originated from a transgenic CD1 random-
bred breeder male mouse (no. 1330) carrying the mutated
rat HER2/neu oncogene driven by the MMTV promoter
[16]. The mutated gene encodes a single point mutation
that replaces the valine residue at position 664 in the
transmembrane (TM) domain of p185/neu with glutamic
acid. This mutation promotes p185/neu homo- and het-
erodimerization and transforms the HER2/neu protoon-
cogene into a dominant transforming oncogene. In these
studies animals were used for tissue harvest only. None-
theless, all animal research was conducted following an
approved protocol filed with the Animal Investigation
Committee at Wayne State University that oversees the
Division of Laboratory Animal Resources (DLAR) at this
institution in strict accordance with NIH guidelines.
Iressa™ and cell lines
"Iressa™" (Zeneca Pharmaceuticals Macclesfield, Chesh-
ire) ZD1839, 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-
(3-morpholinopropoxy) quinazoline was suspended in
DMSO at 10 mM and stored at -20°C until use. Dilutions
were prepared in culture medium to make final concentra-
tions ranging from 0.25–10 µM. The Bam1a cell line has
been previously described and characterized [6].
Establishment and Maintenance of the MAM-1 co-culture 
Model
The MAM-1 co-culture model was established from a
BALB-NeuT transgenic mouse with an advanced mam-
mary gland lobular carcinoma involved with hemorrhage.
The tissue was removed asceptically and rinsed extensively
in sterile PBS. The tissue was minced and dissociated
briefly with collagenase. Cells were washed extensively
with complete medium and explanted into tissue culture
media. Cultures grew in an organization of tumor cell
nests surrounded by myofibroblasts and maintained a
consistent 1:1 ratio of tumor cells to stromal cells. TheseBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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cultures were maintained in vitroin Dulbecco's modified
Eagle's medium (DMEM) with high glucose and supple-
mented with 10% heat inactivated Serum Supreme (Bio-
Whittaker, St. Louis, MO), 0.5 mM sodium pyruvate, 2
mM L-glutamate, 0.1 mM MEM nonessential amino acids,
100 units/ml penicillin and 100 µg/ml streptomycin and
10  µM Dexamethasone. Inclusion of dexamethasone,
impairs the growth of contaminating fibroblasts and
endothelial cells with limited proliferative and immortal-
ization potential. Cells were cultured in 10% CO2, media
was changed every 3–4 days until confluence and split at
a 1:5 ratio for routine passaging. -Co-cultures can be
expected to maintain a 1:1 ratio during active growth. This
ratio may be altered if cultures are kept beyond confluence
when stromal cells continue to grow. At time of passage,
the majority of stromal cells are collected separately by a
brief trypsinization. The remaining co-culture is further
trypsinized and monodispersed and collected separately.
Both collections are counted by hemacytometer which
readily allows for distinguishing between the tumor
(small) and stromal (large) cells. If need be, the cell ratios
can be readjusted to accommodate the desired 1:1 ratio.
All in vitro data presented in this manuscript used MAM-1
between passages 5–20.
Immunohistochemistry
At time of necropsy, tumor tissues were fixed in 10% neu-
tral buffered formalin and paraffin embedded using
standard histochemical techniques. Blocks were sectioned
4-micron. Tissue sections were stained with Hematoxylin
and Eosin for basic histological evaluation. For immuno-
detection of tissue antigens, histological grade primary
antibodies were applied to the samples and incubated
according to manufacturer's recommendation: HER2,
PAD: Z4881, cat# 08-1204 2nd Gen; PCNA, cat# 08-1110
(Zymed, South San Francisco, CA), PCNA Ab-1 clone
(PC10) cat# MS-106-R7; Actin, Smooth Ab-1 (1A4) cat#
MS-113-R7 (Neomarkers, Fremont, CA). Samples were
washed and labeled using the SuperPicTure™ Polymer
Detection Kit, cat#87-9263; Zymed), developed with DAB
Substrate and counterstained with hematoxylin. Samples
were evaluated using a Zeiss microscope and images were
collected through a Sony 970 CCD camera interfaced with
the MCID5+ imaging software package. Alternatively
images were collected using a Nikon inverted microscope
equipped with a SPOT digital cooled camera and imaging
software. Stained sections were evaluated by a board certi-
fied pathologist to generate descriptions.
Flow cytometric analysis of MAM-1 co-cultures
A variety of antibodies were used for flow cytometric anal-
yses. Selection of antibody combinations was based on
fixation, host species, avidity/affinity for specific epitopes
and antigen density. Antibodies used in these studies
included: antibody to the rat Her2/neu (Ab-9, clone B10,
cat# MS-326); erbB-2 (Ab-15, clone 3B5, cat# MS-599,
NeoMarkers, Fremont, CA). CD24 (M1/69) sc-19651-PE;
CD29 (Integrin β1 (HMβ1-1) sc-19656-PE; p-c-Jun
(Ser63)-PE (KM-1) sc-822-PE all from Santa Cruz Biotech-
nology, Santa Cruz, CA. Ready to use histological grade
antibodies that were also used on formaldehyde fixed
samples prepped for flow cytometry or immunofluores-
cence included: (HER2, PAD: Z4881, cat# 08-1204 2nd
Gen; PCNA, cat# 08-1110 Zymed, South San Francisco,
CA). or PCNA Ab-1 clone (PC10) cat# MS-106-R7; Actin,
Smooth Ab-1 (1A4) cat# MS-113-R7 or cat# RB-9010-R7,
Neomarkers, Fremont, CA. Phospho-specific antibodies
from Cell Signaling Technologies, (Beverly, MA) used in
FACS and Immunofluorescence included: p-p44/42 MAP
kinase (Thr202/Tyr204, #9101), p-MEK ½ (Ser217/221.
#9121)
Routine cell surface staining of fresh cell cultures was as
previously described [5]. For evaluation of intracellular
antigens, MAM-1 were plated in 6 well tissue cultures
plates to produce a confluent, organized co-culture (1:1
tumor to stroma cell ratio) within 2–3 days of seeding.
Cells were harvested at specific time points after treatment
with trypsin/EDTA, quenched with complete medium
and collected by centrifugation. Pellets were resuspended
in 1 mL of PBS and monodispersed by passing through a
small bore pipet. Cells were fixed by titrating in 5% For-
maldehyde to a final concentration of 1%, incubated at
37°C for 10 minutes, then chilled on ice for 2 minutes.
Absolute, ice-cold (-20°C) methanol was added while
vortexing to a final concentration of 90%. Samples were
vortexed rigorously and incubated on ice for 30 minutes.
Cells were collected by centrifugation and blocked for 30
minutes on ice with chilled FACscan buffer (PBS supple-
mented with 2% serum and 0.1% sodium azide). Cells
were washed once with fresh FACscan buffer prior to the
addition of primary antibodies or isotype controls and
stained overnight at 4°C in accordance to the manufac-
ture's guidelines. Cells were washed twice and stained
with the appropriate -PE or -FITC conjugated secondary
antibodies: goat anti-mouse IgG-PE, cat# 111-116-144;
donkey anti-rabbit IgG-FITC, cat#711-096-152; donkey
anti-mouse IgG-PE, cat# 715-116-150 (Jackson Immu-
noResearch, West Grove, PA) at 1:50 to 1:200 on ice for 45
min. After staining, samples were washed twice with FAC-
scan buffer, placed on ice and evaluated by flow cytometry
using the dual-color laser option (FL1 v. FL2) in the FAC-
sCaliber. At least 20,000 events were collected for every
sample. Data were analyzed using WinMDI version 2.8
software. Importantly, all experiments were reproduced at
least three times using MAM-1 of different passage num-
bers and overlapping experimental treatments and time
points. The specificities of all stains were validated by
using various combinations of monoclonal and polyclo-
nal antibodies for each antigen and different secondaryBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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labels. All phospho-specific markers and PCNA stains
were evaluated by direct reciprocal dual-staining for the
test antigen with in combination with antibodies to ErbB2
and α-SMA to verify that all ErbB-2 negative responses
were identical to α-SMA positive responses and vice versa.
Immunofluorescence
MAM-1 suspensions were plated on glass cover slips in 6
well plates in complete media and grown to 90–95% of
confluence and treated as described in the text. Following
treatment, cells were fixed and permeabilized by immer-
sion in ice-cold 100% methanol and incubated at -20°C
for 10–20 min. Methanol was aspirated and cover slips
were air-dried, washed and blocked prior to administra-
tion of primary antibodies. Primary antibodies were
diluted and incubated on cover slips according to the rec-
ommendations for each specific antibody. Cover slips
were washed 4 times before adding the secondary FITC- or
TRITC-conjugated goat anti-mouse or rabbit IgG (cat#
115-096-071, 111-096-046, 111-116-144 or 115-116-
071; Jackson ImmunoResearch, West Grove, PA) antibod-
ies diluted 1:50-1:200 in FACscan buffer. Samples were
incubated with secondary for 45 min. at room tempera-
ture in the dark. Stained cover slips were washed and
mounted in Fluorescent mounting media (cat# HT08,
Oncogene Science) containing DAPI for nuclear counter-
staining. Slides were visualized at 100× under oil with a
Zeiss microscope equipped with a Sony 970 digital cooled
camera. Fluorescence photomicrographs were imaged
using MCID5+ software. Live cell images and phase con-
trast of cells fixed in 6-well culture dishes were evaluated
with a Nikon inverted microscope and imaged using the
attached SPOT digital cooled camera and imaging soft-
ware.
Gene Expression Analysis
Total RNA was isolated from triplicate wells of Bam1a
cells [6] or MAM-1 co-cultures that were treated for 24 h
with complete media containing 0 or 1 µM Iressa. Total
RNA was isolated using RNeasy kit (Qiagen, Carlsbad,
CA) and sent to SuperArray Bioscience Corporation (Fre-
derick, MD) and processed utilizing the GEArray Hybridi-
zation and Analysis Service and Agilent Mouse Genome
CGH Microarray 44A that has 43,000+ annotated gene
sequences with well-characterized genes represented by
1+ probes and cancer-relevant genes by 2+ probes. In
some comparisons Universal mouse RNA provided by
Agilent was also used in the analyses for normalization.
Three independent RNA preparations per condition were
analyzed on three separate chips and used to generate the
analysis report. To generate lists of highly expressed genes,
RNA from MAM-1 was labeled in red color (cy5), univer-
sal RNA was labeled in green (cy3). 1) In **treated vs
**control comparison, the treated is labeled in red color
(cy5), control is labeled in green color (cy3). Fold change
(**treated/**control) = Normalized ratio value (cy5/
cy3); fold change cutoff >2 fold (up regulate) or < 1/2
(down regulate); confidence cutoff >0.95.
Results and Discussion
Histological analysis of the primary tumor tissue used to 
derive MAM-1
The tumor was obtained from a BALB-NeuT transgenic
mouse bearing a lesion that involved a hemorrhage of the
#8 thoracic mammary gland. The pathology report
describes the tumor as forming a discrete nodule, most of
which is contained within a thin rim of collagen (pseudo-
capsule) with rare isolated acini penetrating it (Fig. 1A).
The tumor is made of epithelial cells, arranged in ill-
defined nests that are separated by fine fibrous septa. Dis-
crete acini, delimiting central lumens, and filled with
lightly eosinophilic secretions, confer to these epithelial
nests a distinct overall, sieve-like (cribriform) configura-
tion. Necrotic material and focally hemorrhage, fre-
quently accumulates within the tumor, in a punctate
fashion (comedo-type necrosis). Tumor cells show
homogenous cytological features and only mild pleomor-
phism (Fig. 1B). They are polygonal, with a relatively low
N/C ratio, eosinophilic cytoplasm, round central nuclei
with finely dispersed chromatin and infrequent macronu-
cleoli and undergo frequent mitoses. This description is
consistent with the morphology of the lobular carcinomas
that arise in BALB-NeuT transgenic mice [16].
The sample of this lesion that was explanted and proc-
essed for growth in vitro, demonstrates a significant stro-
mal cell component (Fig. 1). By immunohistochemistry
we observed that HER2/neu staining was strong and
present in the majority of the tumor cells (Fig. 1C), in a
cytoplasmic and membranous distribution and that α-
SMA staining was strong and exclusively expressed in the
cytoplasm of the stromal cells that were involved in the
fibrous sheaths surrounding the tumor cell nests (Fig.
1D).
Growth and maintenance of MAM-1 explant cultures
In mice transgenic for the activated rat HER2/neu under
the MMTV promoter, expression of the oncogene in the
mammary gland epithelium gives rise to an alveolar type
of lobular carcinoma that requires an angiogenic switch
for tumor onset and progression to invasive cancer [16].
Coordinated epithelial-stromal interactions that are
required for mammary morphogenesis and development
are also critical for tumor progression in this model. In the
case of human breast cancers, stromal alterations are also
integral to the evolution and progression of breast cancer
[17,18].
Preservation of the breast cancer microenvironment is
critical for evaluating therapeutic agents especially whenBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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Histological analysis of the primary tumor tissue used to derive MAM-1 Figure 1
Histological analysis of the primary tumor tissue used to derive MAM-1. The tumor was obtained from the #8 mam-
mary gland of a BALB-NeuT transgenic mouse. A. Hematoxylin and Eosin staining revealed a prominent fibrovascular response 
associated with the tumor (4×). The tumor forms a discrete nodule within a thin rim of collagen (pseudocapsule). The tumor is 
made of epithelial cells, arranged in ill-defined nests (arrow) that are separated by fine fibrous septa. Discrete acini, delimiting 
central lumens, and filled with lightly eosinophilic secretions, confer to these epithelial nests a distinct overall, sieve-like (cribri-
form) configuration. Necrotic material and focal hemorrhage accumulates within the tumor, in a punctate fashion (comedo-
type necrosis). B. Tumor cells show homogenous cytological features and only mild pleomorphism. They are polygonal, with a 
relatively low N/C ratio, eosinophilic cytoplasm, round central nuclei with finely dispersed chromatin and infrequent macronu-
cleoli and undergo frequent mitoses (40×). C. Immunohistochemical analysis of HER2/neu shows strong staining in the majority 
of the tumor cells, in a cytoplasmic and membranous distribution. D. Immunohistochemical analysis for α-SMA detected strong 
cytoplasmic staining associated exclusively with the stromal cells (arrow) surrounding the tumor cell nests. The antigens were 
detected by DAB (brown) and nuclei counterstained with hematoxylin (blue). Images were photographed under 40× objective.BMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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designing modalities that target invasive disease. Thus, we
sought to establish a homotypic system representing inva-
sive breast cancer by explanting the mammary tumor and
associated stromal cells to develop a co-culture model.
Upon explantation from the tumor, primary cultures that
grew in vitro produced a co-culture that organized as
multi-cell layered nests of tumor cells surrounded by con-
centric rings of stromal cells. These arrangements bear a
striking similarity to the morphology of the primary
tumor lesion (Fig. 2). This configuration was stable and
was able to renew itself under limiting cell dilutions, these
co-cultures were designated as MAM-1.
Passage of MAM-1 stock cultures at a 1:5 ratio maintained
this organized growth pattern to reproducibly generate co-
cultures that consisted of 50% tumor cells and 50% stro-
mal cells. Cultures maintained in this way achieved 95%
confluence within 5–7 days reproducibly for out to 20
passages. There was a tendency for stromal cells to prolif-
erate more rapidly. Excess stromal cell growth was con-
trolled by a mild trypsinization that released the
superficial layer of stromal cells from the culture. At days
3–5 post-confluence, tumor cell nests formed spheroids
that eventually pinched off and were capable of re-estab-
lishing the MAM-1 configuration when plated on fresh tis-
sue culture plastic. Thus, spheroid formation is a natural
progression in this co-culture model and does not require
the elaborate procedures or growth conditions described
for other model systems [8,11,12]. MAM-1 is also capable
of growth in soft agar. However, if not in association with
MAM-1 tumor cells, stromal cells will tend to form mon-
olayers on top of or beneath the agar. One reason for the
faithful renewal of this self-contained co-culture model
can be attributed to the properties of syngeneic tumor
associated stromal cells which have a strong influence on
mammary tumor cell growth and gene expression
[8,11,18]. Further studies are underway, to establish the
genetic relationship between the cells of the stroma and
tumor (i.e. karyotype analysis) and to determine the
potential of each cell type to develop tumors in vivo.
Validation of tumor specific and stroma specific antigens in 
explant cultures by Immunofluorescence and Flow 
cytometry
As suggested by immunohistochemical analysis of the pri-
mary tumor (Fig. 1) we expected the tumor cells in these
co-cultures to express HER2/neu and the stromal cells to
express α-SMA. We observed that expression of HER2/neu
was exclusive to the tumor cell nests with a high level of
distribution in the membrane and cytoplasm (Fig. 2).
HER2/neu expression was at background level in the stro-
mal cells, and α-SMA was strongly expressed in the cyto-
plasmic actin-based microfilaments exclusively in these
cells. In this co-culture setting, strong and consistent
expression of both antigens, tumor-associated HER2/neu
and stromal-associated α-SMA were stable out to 20 pas-
sages. Using these two antigens as markers to identify and
separate tumor from stroma cells, we adapted our staining
method for flow cytometric analysis that would enable us
to evaluate responses in each cell type.
As shown in Fig. 3A, the MAM-1 co-culture is readily frac-
tionated into a HER2/neu+, α-SMA-tumor subpopulation
that accounts for 50–55% of the culture, a HER2-, α-
SMA+ stromal cell population that accounts for 40–45%
of the culture, a HER2/neu+, α-SMA+ population which
may represent a stem cell or cells undergoing mesenchy-
mal transition and typically accounts for 3–5% of the cul-
ture and finally a double negative population that appears
to represent a fibroblast population that typically
accounts for 3–5% of the culture.
Whether or not a "true" mammary stem cell exists in this
co-culture is under investigation. A variety of candidate
mammary stem cell markers are expressed by the different
subpopulations. In mature MAM-1 co-cultures we have
determined that the tumor cell population is HER2/neu+,
CD24lo/med, CD29hi, SMA- and the stromal population is
HER2/neu-, CD24neg, CD29hi, SMA+. Since CD24 nega-
tive, lo and hi populations correspond to nonepithelial,
basal/myoepithelial and luminal epithelial cells respec-
tive [19], we consider our "stromal" cells to be nonepithe-
lial and our "tumor" cells to be a mixture of luminal and
basal/myoepithelial phenotypes. In so much as
CD24+CD29hi  phenotype is enriched in its ability to
reconstitute the essential elements of the mammary
gland, a mammary tumor stem cell-like subpopulation
may be present in these MAM-1 cultures. Since the "onco-
genic" activated rat HER2/neu genetic lesion is expressed
in the mammary stem cell of the donor BALB-NeuT trans-
genic mice, it is possible that this co-culture model may
support a limited degree of cell differentiation from a
stem-like progenitor that is in the HER2/neu positive sub-
population. Further support for a stem cell component in
this self-renewing co-culture model is provided by the
high level of CD44 in MAM-1 and enriched expression of
vimentin and cytokeratin 19 in MAM-1 compared to the
cloned Bam1a cell line described later.
Using flow cytometric analysis we were able to further
subfractionate the HER2/neu (tumor) population based
on their Forward Scatter Profile, which is an index of cell
size. These different size tumor cell subpopulations may
represent cells enriched at different phases of the cell
cycle, smaller cells tend to be enriched for cells in G0 and
larger cells tend to be enriched for cells in G2/M (not
shown). We typically observe an equal distribution of
small (S) and large (L) cell subpopulations in the mam-
mary tumor cell fraction (Fig. 3B). We observed that the
larger cell population (L) had approximately >3-foldBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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Comparison of Tumor tissue morphology in vivo with Explants grown in vitro Figure 2
Comparison of Tumor tissue morphology in vivo with Explants grown in vitro. In Vivo H&E (Top panel) is Hema-
toxylin and Eosin staining of the primary tumor lesion used for generating explant cultures and shows tumor cell nests in a 
fibrofatty matrix within the breast stroma taken with a 10× objective (left) and 25× objective (right). In Vitro Phase Contrast 
photomicrographs (Middle Panel) depict the growth and morphology of MAM-1 explant cultures in vitro. Photomicrographs 
were taken with a (10×, left) or (20×, right) objective. Note in particular the morphological similarities between the explants 
grown in vitro and resemblance to the tumor in vivo. In Vitro Immunofluorescence (Bottom Panel) of MAM-1 grown on cov-
erslips and dual-stained for HER2/neu (FITC, green) and α-SMA (TRITC, red) and counterstained for DAPI depicting the nuclei 
in blue. HER2/neu staining is strong and specific for tumor cells while α-SMA staining is exclusively associated with the cells 
surrounding the tumor cell nests and localized to the actin-based cytoskeleton. Asterisk depicts nucleus of stromal cell for ori-
entation.
HER2/neu α α α α-SMA DAPI
In Vivo H & E
In Vitro Phase Contrast
In Vitro Immunofluorescence
* *
Figure 2, PiechockiBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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Flow Cytometric Analysis of MAM-1 co-cultures. A. Density plot of MAM-1 co-culture stained for HER2/neu and α-SMA Figure 3
Flow Cytometric Analysis of MAM-1 co-cultures. A. Density plot of MAM-1 co-culture stained for HER2/neu 
and α-SMA. MAM-1 co-cultures were stained with the same ready-to-use, histological grade antibodies that were used for 
IHC and IC to detect HER2, PAD: Z4881 and α-SMA, (1A4) in tissues. Primary antibodies were labeled with -PE and FITC con-
jugated secondaries as described in the methods. Quadrant analysis revealed that MAM-1 cultures consisted of 52% HER2/
neu+, α-SMA- tumor cells, 40% HER2/neu-, α-SMA+ stromal cells, a 5% population of HER2/neu-, α-SMA- cells and a 3% popula-
tion of HER2/neu+, α-SMA+ cells which may represent cells undergoing epithelial-mesenchymal transition. At the right, Histo-
gram analysis of the separate FL1 (top) and FL2 (bottom) events indicates 54% of the culture as positive for HER2/neu (top) 
and 43% of cells as positive for α-SMA (bottom) which is consistent with the quadrant analysis. Filled peaks are specific anti-
body stained cells and open peaks represent background staining with the isotype control. B. Subpopulation analysis of Tumor 
cell fractions in MAM-1 co-cultures based on Forward scatter profiles. Dot plot analysis of a-SMA-PE stained cells versus For-
ward scatter indicates the presence of two distinct subpopulations of different size in the a-SMA negative fraction labeled as S 
(small) and L (large). Histogram analysis of these gated subpopulations (defined by the circles) for HER2/neu specific staining 
indicates that the small population has lower levels of HER2/neu, a mean channel fluorescence of 110 compared to the large 
population enriched in dividing cells, with a mean channel fluorescence of 366.
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higher level of HER2/neu expression on the cell surface. If
this subpopulation represents a high proportion of cells
in G2/M antigens and drug responses that are differen-
tially sensitive to the phase of cell cycle can be detected/
identified in the different sized tumor subpopulations (by
forward scatter) and then confirmed and correlated with
further analysis of the cell cycle distribution. For example,
MAM-1 co-cultures that are treated for 1 hour with Iressa
show a redistribution of p-c-Jun (Ser63) to the nucleus
(Fig. 4A) and HER2/neu to the cytosol. In addition to
redistribution from the cytosol, there was an overall
decrease tumor cell associated phospho-c-Jun (i.e., in the
α-SMA negative cells) but not in the α-SMA positive stro-
mal cells (Fig. 4B). The observed 45% decrease in overall
tumor cell phospho-c-Jun resulted from a 46% decrease
that corresponded to the small cells and a 38% decrease in
the large cells. Thus, small, non-dividing cells are about
20% more responsive to Iressa in terms of c-Jun phospho-
rylation. This further implies that large, dividing cells,
which are enriched in HER2/neu receptors (Fig. 3B) and
have a higher baseline level of phospho-c-Jun also have
transient resistance to Iressa at this stage of the cell cycle.
It has been widely documented that dividing cells often
have a higher level of intrinsic resistance to a variety of
chemotherapeutic agents.
The MAM-1 transcriptome has a genetic signature of 
ErbB-2 breast cancers and desmoplasia observed in 
invasive breast cancers
We defined the MAM-1 transcriptome of highly expressed
genes by comparing total RNA from a MAM-1 co-culture
to a commercial preparation of universal mouse RNA
which provides a balanced representation of normal and
cancerous mouse tissues and cell lines. We used a cutoff
value of >2-fold to be considered over-expressed and a p
value cutoff > .05. A comprehensive listing of >2,000
known genes generated in this comparison is provided
[see Additional file 1].
To identify genes associated with the tumor cell and stro-
mal cell subpopulations in these cultures we compared
the gene expression profiles of the Bam1a cell line, a
cloned and characterized mammary carcinoma cell line
developed from a BALB-NeuT mouse [6] and MAM-1 co-
cultures. Bam1a was established from a soft agar colony
and found to be immortal in vitro and tumorigenic in
vivo and highly sensitive to Iressa and anti HER2/neu
antibodies both in vitro and in vivo [6]. We identified
clusters of genes that were highly expressed and common
to Bam1a and MAM-1 co-cultures or differentially
expressed between Bam1a and MAM-1. Table 1 is a repre-
sentation of genes that are highly expressed by Bam1a and
MAM-1 and part of the "ErbB-2 Signature" that is associ-
ated with many ErbB-2 expressing breast cancers [20-23].
In most instances the relative expression level of these sig-
nature genes was similar (within 2-fold) between Bam1a
and MAM-1. This two-fold difference is likely to represent
the dilution of tumor cell RNA with stromal cell RNA in
the MAM-1 co-culture.
Genes uniquely over-expressed by MAM-1 largely reflect
the stromal signature of this breast cancer co-culture sys-
tem. A select list of ~563 differentially expressed genes is
provided [see Additional file 2]. We considered only dif-
ferences greater than 3-fold to compensate for the dilution
of tumor and stroma specific RNA in the MAM-1 cultures
when compared to the cloned cell line, Bam1a. Certain
genes that are uniquely over-expressed in Bam1a are likely
to reflect the influence of co-culture on the gene-expres-
sion patterns. Paradoxically, for example, we observe >25-
fold higher expression of EPSTI1 in Bam1a compared to
MAM-1, which contradicts what is typically observed and
expected [12]. A majority of the genes that are over-
expressed in MAM-1 have been identified in tumor asso-
ciated fibroblasts and stromal cells and represent genes
involved in the fibrotic response and basement mem-
brane synthesis [24,25]. In particular, collagen genes
involved in fibrosis and contraction and growth factors
that stimulate the fibrotic response. In addition, genes
involved in remodeling the extracellular matrix, including
ADAM and MMP family members are highly represented.
When we compared genes differentially expressed
between Bam1a and MAM-1 to genes clusters used to
determine the stromal signatures of breast cancers, we
found that relative to Bam1a, MAM-1 over-expressed 70%
of the genes associated with the desmoid-type fibromato-
sis signature described by West et al. [24] including
WISP2, COL1A1, COL5A1, COL3A1, COL6A1, MMP23,
MMP19,  CNN1,  CTGF,  ADAM19,  FBN1  and  ADAM12
(Table 2). This cluster of stroma specific genes, also iden-
tifies subgroups of breast carcinomas with a more favora-
ble outcome when compared to the solitary fibrous tumor
cluster [24] Further analyses revealed similarities between
MAM-1 and an invasion specific cluster that is associated
with the desmoplastic response to invading breast cancer
[25] (Table 2). In particular, we observe >20-fold over-
expression of COL1A1,  IGFBP7  and  SPARC  in MAM-1
which are correlated with panstromal and juctatumoral
stromal cell responses involved in matrix remodeling and
angiogenesis, respective. These data are consistent with
the histological features of the primary lesion used to
establish MAM-1 and demonstrate the preserved expres-
sion of invasion specific genes in the MAM-1 co-culture.
We also observed upregulation of a variety of stroma spe-
cific genes associated with tumor progression, invasion
and the malignant phenotype in MAM-1. These include,
MMP2  [10,18]ADAM12  [26],  HAS2, [27] and CLIC4
[28,29]. Others have also demonstrated that heterologous
co-cultures of breast tumor cells with tumor-derivedBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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Evaluation of p-c-Jun (Ser63) levels and subcellular distribution in MAM-1 co-cultures treated with Iressa by A. Immunofluores- cence and B. Flow Cytometry Figure 4
Evaluation of p-c-Jun (Ser63) levels and subcellular distribution in MAM-1 co-cultures treated with Iressa by A. 
Immunofluorescence and B. Flow Cytometry. MAM-1 were subcultured on coverslips or in 6-well plates and grown to 
~95% confluence and then treated by replacing the conditioned media with fresh media that contained diluent (.001% DMSO, 
Control) or 1 µM Iressa for 1 hour prior to fixing and evaluation as described in the methods. A. Immunofluorescent photom-
icrographs were taken with the 100× objective under oil immersion of cells that were double labeled for p-c-Jun (Ser63) in red 
(TRITC) and HER2/neu in green (FITC) and counterstained with DAPI (blue) to define the nuclei. B. Flow cytometric analysis 
of control (left) and Iressa-treated (right) MAM-1 cultures. Cells were dual labeled for p-c-Jun (Ser63) and α-SMA. Density 
plots compare p-c-Jun (Ser63) expression levels in the α-SMA negative and positive subpopulations in control and Iressa-
treated MAM-1 cultures. Mean Channel fluorescent values for p-c-Jun (Ser63) are indicated in the respective quadrants. Histo-
gram analyses for p-c-Jun (Ser63) expression in the α-SMA negative subpopulations were generated from dot plots of p-Jun 
(Ser63)-PE versus Forward Scatter and gating on the respective the S (small) and L (large) fractions. Histograms of these tumor 
cell subpopulations demonstrate different baseline levels (Left) of p-c-Jun (Ser63) levels and Iressa responsiveness (Right) in 
small (S) and large (L) cells. Mean channel fluorescent values for p-c-Jun (Ser63) levels are indicated above the peaks. Parallel 
samples were dual stained for HER2/neu and p-c-Jun (Ser63) to verify these data (not shown).
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Table 1: Expression of HER2/neu ErbB-2 Breast Cancer Signature genes in MAM-1 Co-cultures and the Bam1a cell line
Expression Relative to Universal Mouse RNAa
Agilent Accession Genbank Accession MAM Bam1a Gene Description and Symbol
Genes present in the tumor-specific HER-2/neu-Induced Gene Expression Signature described by Astolfi
A_51_P184886 NM_011920 5.27 19.10 Mus musculus ATP-binding cassette, sub-family G (WHITE), member 
2 (Abcg2), mRNA [NM_011920]
A_52_P336142 NM_011920 4.90 17.77 Mus musculus ATP-binding cassette, sub-family G (WHITE), member 
2 (Abcg2), mRNA [NM_011920]
A_51_P342567 NM_031185 9.10 6.60 Mus musculus A kinase (PRKA) anchor protein (gravin) 12 (Akap12), 
mRNA [NM_031185]
A_51_P445166 NM_019959 11.89 17.02 Mus musculus C1q and tumor necrosis factor related protein 1 
(C1qtnf1), mRNA [NM_019959]
A_51_P455647 NM_009801 7.56 9.21 Mus musculus carbonic anhydrase 2 (Car2), mRNA [NM_009801]
A_51_P303160 NM_007482 14.32 23.23 Mus musculus arginase 1, liver (Arg1), mRNA [NM_007482]
A_52_P159232 NM_011926 20.60 24.52 Mus musculus CEA-related cell adhesion molecule 1 (Ceacam1), 
mRNA [NM_011926]
A_51_P183446 NM_001039185 10.69 12.16 Mus musculus CEA-related cell adhesion molecule 1, mRNA (cDNA 
clone MGC:18556 IMAGE:4218391), complete cds [BC016891]
A_51_P171728 NM_011926 9.77 12.34 Mus musculus CEA-related cell adhesion molecule 1 (Ceacam1), 
mRNA [NM_011926]
A_52_P240706 NM_007543 23.70 31.29 Mus musculus CEA-related cell adhesion molecule 2 (Ceacam2), 
mRNA [NM_007543]
A_51_P362066 NM_007695 8.34 3.89 Mus musculus chitinase 3-like 1 (Chi3l1), mRNA [NM_007695]
A_51_P495049 NM_009897 10.34 11.46 Mus musculus creatine kinase, mitochondrial 1, ubiquitous (Ckmt1), 
mRNA [NM_009897]
A_51_P343309 NM_009908 5.83 10.54 Mus musculus cytidine monophospho-N-acetylneuraminic acid 
synthetase (Cmas), mRNA [NM_009908]
A_52_P197963 NM_009936 7.33 10.23 Mus musculus procollagen, type IX, alpha 3 (Col9a3), mRNA 
[NM_009936]
A_52_P507877 NM_007729 41.31 30.23 Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA 
[NM_007729]
A_51_P459477 NM_007729 34.68 28.45 Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA 
[NM_007729]
A_51_P227280 NM_007786 53.04 56.89 Mus musculus casein kappa (Csnk), mRNA [NM_007786]
A_51_P227275 NM_007786 26.87 32.53 Mus musculus casein kappa (Csnk), mRNA [NM_007786]
A_52_P51078 NM_007801 23.49 35.47 Mus musculus cathepsin H (Ctsh), mRNA [NM_007801]
A_51_P275976 NM_010070 3.24 Mus musculus docking protein 1 (Dok1), mRNA [NM_010070]
A_52_P366842 NM_010070 2.49 4.94 Mus musculus docking protein 1 (Dok1), mRNA [NM_010070]
A_51_P158037 NM_013505 11.59 12.52 Mus musculus desmocollin 2 (Dsc2), mRNA [NM_013505]
A_52_P157158 NM_013505 42.42 46.62 Mus musculus desmocollin 2 (Dsc2), mRNA [NM_013505]
A_52_P252931 NM_013505 107.26 265.33 Mus musculus desmocollin 2 (Dsc2), mRNA [NM_013505]
A_51_P502614 NM_026268 4.28 6.46 Mus musculus dual specificity phosphatase 6 (Dusp6), mRNA 
[NM_026268]
A_51_P455866 NM_010125 27.80 29.60 Mus musculus E74-like factor 5 (Elf5), mRNA [NM_010125]
A_51_P307979 NM_007960 2.46 Mus musculus ets variant gene 1 (Etv1), mRNA [NM_007960]
A_51_P246166 NM_007969 10.06 10.23 Mus musculus extracellular proteinase inhibitor (Expi), mRNA 
[NM_007969]
A_52_P329207 NM_007969 13.14 12.84 Mus musculus extracellular proteinase inhibitor (Expi), mRNA 
[NM_007969]
A_51_P329394 NM_008034 6.64 8.48 Mus musculus folate receptor 1 (adult) (Folr1), mRNA [NM_008034]
A_52_P377791 NM_008557 30.34 40.63 Mus musculus FXYD domain-containing ion transport regulator 3 
(Fxyd3), mRNA [NM_008557]
A_51_P282538 NM_008077 28.43 73.47 Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA 
[NM_008077]
A_52_P144310 NM_008077 27.33 68.46 Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA 
[NM_008077]
A_51_P486810 NM_030677 13.90 14.97 Mus musculus glutathione peroxidase 2 (Gpx2), mRNA 
[NM_030677]
A_51_P258409 NM_010423 13.98 30.78 Mus musculus hairy/enhancer-of-split related with YRPW motif 1 
(Hey1), mRNA [NM_010423]
A_51_P365152 NM_010474 23.53 48.48 Mus musculus heparan sulfate (glucosamine) 3-O-sulfotransferase 1 
(Hs3st1), mRNA [NM_010474]
A_52_P281702 NM_010518 2.12 3.08 Mus musculus insulin-like growth factor binding protein 5 (Igfbp5), 
mRNA [NM_010518]
A_51_P204153 NM_010518 4.25 10.70 Mus musculus insulin-like growth factor binding protein 5 (Igfbp5), 
mRNA [NM_010518]
A_51_P510156 NM_008491 9.56 10.11 Mus musculus lipocalin 2 (Lcn2), mRNA [NM_008491]
A_52_P153864 NM_010723 2.77 3.75 Mus musculus LIM domain only 4 (Lmo4), mRNA [NM_010723]
A_51_P394190 NM_010723 3.05 4.24 Mus musculus LIM domain only 4 (Lmo4), mRNA [NM_010723]
A_52_P415168 NM_019394 8.35 8.26 Mus musculus melanoma inhibitory activity 1 (Mia1), mRNA 
[NM_019394]
A_52_P415167 NM_019394 18.65 22.26 Mus musculus melanoma inhibitory activity 1 (Mia1), mRNA 
[NM_019394]
A_52_P174346 NM_019394 7.84 8.15 Mus musculus melanoma inhibitory activity 1 (Mia1), mRNA 
[NM_019394]BMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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A_51_P220062 NM_008609 10.60 15.42 Mus musculus matrix metalloproteinase 15 (Mmp15), mRNA 
[NM_008609]
A_51_P139780 NM_009402 6.81 7.64 Mus musculus peptidoglycan recognition protein 1 (Pglyrp1), mRNA 
[NM_009402]
A_51_P195958 NM_009344 3.26 6.05 Mus musculus pleckstrin homology-like domain, family A, member 1 
(Phlda1), mRNA [NM_009344]
A_52_P418791 NM_011254 15.11 16.38 Mus musculus retinol binding protein 1, cellular (Rbp1), mRNA 
[NM_011254]
A_51_P423484 NM_011254 8.26 7.45 Mus musculus retinol binding protein 1, cellular (Rbp1), mRNA 
[NM_011254]
A_52_P197215 NM_028777 2.76 4.29 Mus musculus SEC14-like 1 (S. cerevisiae) (Sec14l1), mRNA 
[NM_028777]
A_52_P197223 NM_028777 3.32 5.72 Mus musculus SEC14-like 1 (S. cerevisiae) (Sec14l1), mRNA 
[NM_028777]
A_51_P268094 NM_009255 22.21 38.32 Mus musculus serine (or cysteine) proteinase inhibitor, clade E, 
member 2 (Serpine2), mRNA [NM_009255]
A_52_P637988 NM_009199 40.88 62.00 Mus musculus solute carrier family 1 (neuronal/epithelial high affinity 
glutamate transporter, system Xag), member 1 (Slc1a1), mRNA 
[NM_009199]
A_51_P110759 NM_009199 20.06 26.16 Mus musculus solute carrier family 1 (neuronal/epithelial high affinity 
glutamate transporter, system Xag), member 1 (Slc1a1), mRNA 
[NM_009199]
A_52_P426605 NM_021301 23.10 30.57 Mus musculus solute carrier family 15 (H+/peptide transporter), 
member 2 (Slc15a2), mRNA [NM_021301]
A_51_P107362 NM_007706 13.23 14.79 Mus musculus suppressor of cytokine signaling 2 (Socs2), mRNA 
[NM_007706]
A_51_P346704 XM_128139 10.67 11.19 Mus musculus SRY-box containing gene 10, mRNA (cDNA clone 
MGC:32314 IMAGE:5027211), complete cds. [BC023356]
A_52_P192625 XM_128139 23.80 36.33 Mus musculus SRY-box containing gene 10, mRNA (cDNA clone 
MGC:32314 IMAGE:5027211), complete cds. [BC023356]
A_52_P161630 NM_145933 4.23 Mus musculus beta galactoside alpha 2,6 sialyltransferase 1 (St6gal1), 
mRNA [NM_145933]
A_51_P101375 NM_145933 2.35 5.29 Mus musculus beta galactoside alpha 2,6 sialyltransferase 1 (St6gal1), 
mRNA [NM_145933]
A_51_P183940 NM_016866 2.21 3.02 Mus musculus serine/threonine kinase 39, STE20/SPS1 homolog 
(yeast) (Stk39), mRNA [NM_016866]
A_52_P447944 NM_008532 5.04 8.96 Mus musculus tumor-associated calcium signal transducer 1 
(Tacstd1), mRNA [NM_008532]
A_51_P418820 NM_009335 40.16 37.90 Mus musculus transcription factor AP-2, gamma (Tcfap2c), mRNA 
[NM_009335]
A_51_P338262 NM_011619 5.37 8.17 Mus musculus troponin T2, cardiac (Tnnt2), mRNA [NM_011619]
A_51_P482503 NM_009413 21.46 34.02 Mus musculus tumor protein D52-like 1 (Tpd52l1), mRNA 
[NM_009413]
A_51_P506822 NM_011674 42.90 81.82 Mus musculus UDP galactosyltransferase 8A (Ugt8a), mRNA 
[NM_011674]
A_52_P439263 NM_011674 56.91 70.50 Mus musculus UDP galactosyltransferase 8A (Ugt8a), mRNA 
[NM_011674]
Genes expressed in common with the mouse orthologs of the human "intrinsic" gene list of published by Sorlie
A_51_P311038 NM_001024139 7.11 9.21 Mus musculus a disintegrin-like and metalloprotease (reprolysin type) 
with thrombospondin type 1 motif, 15 (Adamts15), mRNA 
[NM_001024139]
A_51_P366811 NM_007470 45.17 36.20 Mus musculus apolipoprotein D (Apod), mRNA [NM_007470]
A_51_P163015 NM_172309 2.77 14.02 Mus musculus aryl hydrocarbon receptor nuclear translocator-like 2 
(Arntl2), mRNA [NM_172309]
A_51_P455647 NM_009801 7.57 9.21 Mus musculus carbonic anhydrase 2 (Car2), mRNA [NM_009801]
A_51_P302823 NM_019686 4.02 11.39 Mus musculus calcium and integrin binding family member 2 (Cib2), 
mRNA [NM_019686]
A_51_P165185 NM_016887 11.54 15.50 Mus musculus claudin 7 (Cldn7), mRNA [NM_016887]
A_52_P507877 NM_007729 41.32 30.23 Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA 
[NM_007729]
A_51_P459477 NM_007729 34.69 28.45 Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA 
[NM_007729]
A_51_P502614 NM_026268 4.28 6.46 Mus musculus dual specificity phosphatase 6 (Dusp6), mRNA 
[NM_026268]
A_51_P116940 NM_007940 15.92 5.95 Mus musculus epoxide hydrolase 2, cytoplasmic (Ephx2), mRNA 
[NM_007940]
A_51_P455932 NM_007974 12.81 33.87 Mus musculus coagulation factor II (thrombin) receptor-like 1 (F2rl1), 
mRNA [NM_007974]
A_52_P192418 NM_010175 2.63 4.90 Mus musculus Fas (TNFRSF6)-associated via death domain (Fadd), 
mRNA [NM_010175]
A_51_P382925 NM_010175 2.16 3.61 Mus musculus Fas (TNFRSF6)-associated via death domain (Fadd), 
mRNA [NM_010175]
A_52_P100252 NM_007988 3.23 3.40 Mus musculus clone:A630082H08 product:fatty acid synthase, full 
insert sequence. [AK080374]
A_52_P136162 NM_010206 2.27 4.37 Mus musculus fibroblast growth factor receptor 1 (Fgfr1), mRNA 
[NM_010206]
Table 1: Expression of HER2/neu ErbB-2 Breast Cancer Signature genes in MAM-1 Co-cultures and the Bam1a cell line (Continued)BMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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A_52_P668810 NM_010206 3.81 Mus musculus fibroblast growth factor receptor 1 (Fgfr1), mRNA 
[NM_010206]
A_51_P335000 NM_010211 5.05 Mus musculus four and a half LIM domains 1 (Fhl1), mRNA 
[NM_010211]
A_51_P329394 NM_008034 6.64 8.48 Mus musculus folate receptor 1 (adult) (Folr1), mRNA [NM_008034]
A_52_P217710 NM_008056 3.08 Mus musculus frizzled homolog 6 (Drosophila) (Fzd6), mRNA 
[NM_008056]
A_51_P282538 NM_008077 28.43 73.47 Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA 
[NM_008077]
A_52_P144310 NM_008077 27.33 68.46 Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA 
[NM_008077]
A_51_P380005 NM_015736 32.95 69.29 Mus musculus UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (Galnt3), mRNA [NM_015736]
A_51_P379997 NM_015736 38.50 82.09 Mus musculus UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (Galnt3), mRNA [NM_015736]
A_51_P462422 NM_008124 5.07 Mus musculus gap junction membrane channel protein beta 1 (Gjb1), 
mRNA [NM_008124]
A_52_P16419 NM_010271 2.43 6.66 Mus musculus glycerol-3-phosphate dehydrogenase 1 (soluble) 
(Gpd1), mRNA [NM_010271]
A_52_P415996 NM_008184 6.29 Mus musculus glutathione S-transferase, mu 6 (Gstm6), mRNA 
[NM_008184]
A_51_P179664 NM_008185 3.67 6.80 Mus musculus glutathione S-transferase, theta 1 (Gstt1), mRNA 
[NM_008185]
A_52_P281702 NM_010518 2.12 3.08 Mus musculus insulin-like growth factor binding protein 5 (Igfbp5), 
mRNA [NM_010518]
A_51_P204153 NM_010518 4.25 10.70 Mus musculus insulin-like growth factor binding protein 5 (Igfbp5), 
mRNA [NM_010518]
A_52_P401386 NM_010593 3.74 5.28 Mus musculus junction plakoglobin (Jup), mRNA [NM_010593]
A_52_P642488 NM_008430 24.28 26.37 Mus musculus potassium channel, subfamily K, member 1 (Kcnk1), 
mRNA [NM_008430]
A_51_P307964 NM_010662 3.11 6.39 Mus musculus keratin complex 1, acidic, gene 13 (Krt1-13), mRNA 
[NM_010662]
A_51_P324814 NM_010664 2.93 3.89 Mus musculus keratin complex 1, acidic, gene 18 (Krt1-18), mRNA 
[NM_010664]
A_52_P410685 NM_033073 12.42 14.59 Mus musculus keratin complex 2, basic, gene 7 (Krt2-7), mRNA 
[NM_033073]
A_51_P242400 NM_031170 2.56 3.75 Mus musculus keratin complex 2, basic, gene 8 (Krt2-8), mRNA 
[NM_031170]
A_51_P174943 NM_008485 6.90 10.66 Mus musculus laminin, gamma 2 (Lamc2), mRNA [NM_008485]
A_51_P220062 NM_008609 10.60 15.42 Mus musculus matrix metalloproteinase 15 (Mmp15), mRNA 
[NM_008609]
A_51_P514085 NM_013606 3.75 6.35 Mus musculus myxovirus (influenza virus) resistance 2 (Mx2), mRNA 
[NM_013606]
A_52_P608097 NM_008756 17.70 41.15 Mus musculus occludin (Ocln), mRNA [NM_008756]
A_51_P486150 NM_008756 10.05 12.72 Mus musculus occludin (Ocln), mRNA [NM_008756]
A_52_P458279 NM_011169 15.09 21.23 Mus musculus prolactin receptor (Prlr), mRNA [NM_011169]
A_51_P248345 NM_009334 17.92 Mus musculus transcription factor AP-2 beta (Tcfap2b), transcript 
variant 1, mRNA [NM_009334]
A_51_P418820 NM_009335 40.16 37.90 Mus musculus transcription factor AP-2, gamma (Tcfap2c), mRNA 
[NM_009335]
A_51_P240614 NM_008536 3.79 5.43 Mus musculus transmembrane 4 superfamily member 1 (Tm4sf1), 
mRNA [NM_008536]
A_51_P482503 NM_009413 21.46 34.02 Mus musculus tumor protein D52-like 1 (Tpd52l1), mRNA 
[NM_009413]
A_51_P106059 NM_009423 2.81 3.48 Mus musculus Tnf receptor associated factor 4 (Traf4), mRNA 
[NM_009423]
A_52_P78403 NM_009423 2.90 5.78 Mus musculus Tnf receptor associated factor 4 (Traf4), mRNA 
[NM_009423]
Genes expressed in common with the MMTV/neu mammary tumor gene signature described by Landis
A_51_P320852 NM_007657 2.52 7.50 Mus musculus CD9 antigen (Cd9), mRNA [NM_007657]
A_51_P242265 NM_009950 2.45 4.36 Mus musculus CASP2 and RIPK1 domain containing adaptor with 
death domain (Cradd), mRNA [NM_009950]
A_52_P559779 NM_007883 17.30 22.26 Mus musculus desmoglein 2 (Dsg2), mRNA [NM_007883]
A_51_P249848 NM_007883 11.40 13.77 Mus musculus desmoglein 2 (Dsg2), mRNA [NM_007883]
A_52_P88091 NM_007883 22.00 38.20 Mus musculus desmoglein 2 (Dsg2), mRNA [NM_007883]
A_52_P601757 NM_007883 76.45 101.83 Mus musculus desmoglein 2, mRNA (cDNA clone IMAGE:4036406), 
partial cds [BC034056]
A_51_P502614 NM_026268 4.28 6.46 Mus musculus dual specificity phosphatase 6 (Dusp6), mRNA 
[NM_026268]
A_51_P246166 NM_007969 10.06 10.23 Mus musculus extracellular proteinase inhibitor (Expi), mRNA 
[NM_007969]
A_52_P329207 NM_007969 13.14 12.84 Mus musculus extracellular proteinase inhibitor (Expi), mRNA 
[NM_007969]
A_51_P329394 NM_008034 6.64 8.48 Mus musculus folate receptor 1 (adult) (Folr1), mRNA [NM_008034]
A_51_P352303 NM_011983 5.94 8.58 Mus musculus homer homolog 2 (Drosophila) (Homer2), mRNA 
[NM_011983]
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A_52_P176573 NM_011983 7.52 12.27 Mus musculus homer homolog 2 (Drosophila) (Homer2), mRNA 
[NM_011983]
A_51_P510156 NM_008491 9.56 10.11 Mus musculus lipocalin 2 (Lcn2), mRNA [NM_008491]
A_52_P382785 NM_033525 3.71 12.17 Mus musculus nephronectin (Npnt), mRNA [NM_033525]
A_51_P289889 NM_033525 3.57 9.38 Mus musculus nephronectin (Npnt), mRNA [NM_033525]
A_52_P17556 NM_134249 6.84 18.37 Mus musculus T-cell immunoglobulin and mucin domain containing 2 
(Timd2), mRNA [NM_134249]
A_51_P500906 NM_134249 12.27 24.24 Mus musculus T-cell immunoglobulin and mucin domain containing 2 
(Timd2), mRNA [NM_134249]
A_51_P482503 NM_009413 21.46 34.02 Mus musculus tumor protein D52-like 1 (Tpd52l1), mRNA 
[NM_009413]
Expression of genes associated with the human HER2/neu chromosome 17q amplicon by Bertucci
A_51_P317176 NM_009971 12.40 13.05 Mus musculus colony stimulating factor 3 (granulocyte) (Csf3), 
mRNA [NM_009971]
A_51_P216179 NM_010152 4.71 8.69 Mus musculus v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2, neuro/glioblastoma derived oncogene homolog (avian) 
(Erbb2), transcript variant 2, mRNA [NM_010152]
A_51_P230382 NM_008815 2.63 3.66 Mus musculus ets variant gene 4 (E1A enhancer binding protein, 
E1AF) (Etv4), mRNA [NM_008815]
A_51_P368823 NM_010346 3.09 4.64 Mus musculus growth factor receptor bound protein 7 (Grb7), 
mRNA [NM_010346]
A_52_P401386 NM_010593 3.74 5.28 Mus musculus junction plakoglobin (Jup), mRNA [NM_010593]
A_52_P567306 NM_010688 2.95 4.98 Mus musculus LIM and SH3 protein 1 (Lasp1), mRNA [NM_010688]
A_51_P182462 NM_010688 2.46 3.44 Mus musculus LIM and SH3 protein 1 (Lasp1), mRNA [NM_010688]
A_51_P387123 NM_011854 2.77 4.06 Mus musculus 2'-5' oligoadenylate synthetase-like 2 (Oasl2), mRNA 
[NM_011854]
aAverage fold difference is the ratio (n = 3, p value cutoff > .05) MAM-1 or Bam1a RNA to Universal Mouse RNA. RNA from MAM-1 or Bam1a was 
labeled in red color (cy5), universal RNA is labeled in green (cy3). Three independent RNA preparations per condition were analyzed on three 
separate chips and averaged; a confidence cutoff of >0.95 was used for the raw values of red/green before normalization. The fold change (**MAM-
1 or Bam1a/**Universal Mouse) = Normalized ratio value(cy5/cy3). The MAM-1 and Bam1a transcriptomes include genes that are differentially 
increased relative to the Universal mouse RNA by at least 2-fold.
Table 1: Expression of HER2/neu ErbB-2 Breast Cancer Signature genes in MAM-1 Co-cultures and the Bam1a cell line (Continued)
fibroblasts (but not normal skin fibroblasts) was required
for myofibroblast differentiation (i.e., expression of
alpha-SMA) and resembled the advanced stages of desmo-
plastic carcinomas [11], similar to what we observe in the
homotypic MAM-1 co-culture model. In these studies,
expression of PMP22 was identified as a candidate gene in
modulating tumor cell interactions with fibroblast. In
MAM-1, PMP22 is upregulated approximately 15-fold and
thus, may also play a role in the MAM-1 model.
Effect of Iressa on signal transduction in MAM-1
Western blot and microarray analyses revealed differential
expression of the HER2/neu and EGFR in the respective
tumor and stroma fractions of MAM-1 co-cultures. HER2/
neu was exclusively expressed in the mammary tumor cell
fraction and EGFR was approximately 8-fold higher in the
stromal cell population. In so much as the EGFR is
approximately 50-fold more sensitive to Iressa
(IC50>0.080  µM) compared to the c-erbB-2 tyrosine
kinase (IC50~3 µM) in vitro, we anticipated that EGFR in
the stromal cell population was a likely target for the
inhibitory activities of Iressa. Indeed, it has been sug-
gested that targeting tumor associated fibroblasts [30] and
the stromal EGFR may be a viable approach for preventing
tumor progression and impeding the angiogenic switch. It
has been shown that Iressa can differentially modulate
fibrosis in various models of injury and disease [31-33]. It
is important to distinguish, that in most injury models,
the fibroblasts that are targeted as effectors of fibrosis are
normal stromal fibroblasts and not phenotypically simi-
lar to the cancer associated fibroblasts/myofibroblasts
that represent the stromal cells in the MAM-1 model. We
expected that the response to Iressa in the MAM-1 stromal
cells could be effected by their intrinsic sensitivity to Iressa
and the microenvironment. Thus, we used the MAM-1 co-
culture model to determine the selectivity and specificity
of Iressa for the HER2/neu over-expressing mammary
tumor cells versus the EGFR-expressing stromal cells by
evaluating signal transduction downstream of these RTKs.
In MAM-1 co-cultures that are stimulated by replacing the
culture medium, strong cytoplasmic expression of phos-
phorylated p44/42 MAPK is readily observed (Fig. 5A).
Inclusion of 1 µM Iressa eliminates this response. By flow
cytometric analysis we determined the dose-response for
p44/42 MAPK and pMEK1/2 in the ErbB-2+ (tumor cell)
and ErbB-2-(stromal cell) subpopulations in MAM-1 co-
cultures. We observed a dose-dependent decrease in
pp44/42 MAPK and pMEK1/2 phosphorylation in tumor
cells with maximal decreases of 90% and 40%, respective
(Fig. 5B). We also observed a modest (38%) decrease in
stromal cell phospho-pp44/42 MAPK at all doses of Iressa
but no effect of pMEK1/2 phosphorylation, suggesting a
small inhibitory effect of Iressa on the EGFR in the stroma.BMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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Table 2: Differentially expressed Fibromatosis and Desmoplastic response genes in the MAM-1 Transcriptome
Agilent Accession Genbank Accession Ratio of MAM-1 
vs. Bam1a
p-value (n = 3) Gene Description and Symbol Reference
A_51_P162272 NM_009524 5.95 2.58E-03 Mus musculus wingless-related MMTV integration 
site 5A (Wnt5a), mRNA [NM_009524]
West
A_51_P390804 NM_016873 125.00 8.89E-06 Mus musculus WNT1 inducible signaling pathway 
protein 2 (Wisp2), mRNA [NM_016873]
West
A_51_P220343 NM_018865 16.66 4.06E-06 Mus musculus WNT1 inducible signaling pathway 
protein 1 (Wisp1), mRNA [NM_018865]
West
A_52_P658611 NM_007742 19.92 4.09E-03 Mus musculus procollagen, type I, alpha 1 
(Col1a1), mRNA [NM_007742]
West, Iacobuzio-Donahue
A_52_P525107 NM_007742 187.97 1.12E-05 Mus musculus procollagen, type I, alpha 1 
(Col1a1), mRNA [NM_007742]
West, Iacobuzio-Donahue
A_51_P377094 NM_007742 37.17 9.02E-08 Mus musculus procollagen, type I, alpha 1 
(Col1a1), mRNA [NM_007742]
West, Iacobuzio-Donahue
A_51_P414637 NM_015734 168.63 7.15E-06 Mus musculus procollagen, type V, alpha 1 
(Col5a1), mRNA [NM_015734]
West
A_52_P684242 NM_009930 4.93 7.45E-05 Mus musculus procollagen, type III, alpha 1 
(Col3a1), mRNA [NM_009930]
West
A_51_P515605 NM_009930 94.34 1.67E-09 Mus musculus procollagen, type III, alpha 1 
(Col3a1), mRNA [NM_009930]
West
A_51_P474496 NM_009933 12.21 6.30E-08 Mus musculus procollagen, type VI, alpha 1 
(Col6a1), mRNA [NM_009933]
West
A_51_P502132 NM_011985 7.69 1.96E-07 Mus musculus matrix metalloproteinase 23 
(Mmp23), mRNA [NM_011985]
West
A_51_P269166 NM_021412 13.33 1.11E-02 Mus musculus matrix metalloproteinase 19 
(Mmp19), mRNA [NM_021412]
West
A_51_P293087 NM_008606 4.76 7.12E-06 Mus musculus matrix metalloproteinase 11 
(Mmp11), mRNA [NM_008606]
West
A_51_P404077 NM_020510 3.45 3.09E-06 Mus musculus frizzled homolog 2 (Drosophila) 
(Fzd2), mRNA [NM_020510]
West
A_52_P597634 NM_021457 4.55 5.25E-07 Mus musculus frizzled homolog 1 (Drosophila) 
(Fzd1), mRNA [NM_021457]
West
A_52_P224801 NM_007993 130.03 1.47E-03 Mus musculus fibrillin 1 (Fbn1), mRNA 
[NM_007993]
West
A_51_P467224 NM_007993 240.38 8.77E-05 Mus musculus fibrillin 1 (Fbn1), mRNA 
[NM_007993]
West
A_52_P220176 NM_015814 20.88 3.70E-02 Mus musculus dickkopf homolog 3 (Xenopus 
laevis) (Dkk3), mRNA [NM_015814]
West
A_52_P489295 NM_009621 4.22 2.72E-05 Mus musculus a disintegrin-like and 
metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 1 (Adamts1), 
mRNA [NM_009621]
West
A_52_P213932 NM_009621 3.10 1.94E-05 Mus musculus a disintegrin-like and 
metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 1 (Adamts1), 
mRNA [NM_009621]
West
A_52_P280044 NM_009616 16.21 1.63E-05 Mus musculus a disintegrin and metalloproteinase 
domain 19 (meltrin beta) (Adam19), mRNA 
[NM_009616]
West
A_51_P267447 NM_009616 10.35 8.95E-04 Mus musculus a disintegrin and metalloproteinase 
domain 19 (meltrin beta) (Adam19), mRNA 
[NM_009616]
West
A_52_P290457 NM_007400 33.11 4.05E-03 Mus musculus a disintegrin and metalloproteinase 
domain 12 (meltrin alpha) (Adam12), mRNA 
[NM_007400]
West, Peduto
A_51_P510882 NM_007400 9.35 1.38E-03 Mus musculus a disintegrin and metalloproteinase 
domain 12 (meltrin alpha) (Adam12), mRNA 
[NM_007400]
West, Peduto
A_51_P350817 NM_009922 38.46 1.29E-04 Mus musculus calponin 1 (Cnn1), mRNA 
[NM_009922]
West
A_52_P599578 NM_145575 1.24 1.03E-02 Mus musculus caldesmon 1 (Cald1), mRNA 
[NM_145575]
West
A_51_P357573 NM_145575 1.25 3.07E-02 Mus musculus caldesmon 1 (Cald1), mRNA 
[NM_145575]
West
A_51_P157042 NM_010217 14.33 1.71E-04 Mus musculus connective tissue growth factor 
(Ctgf), mRNA [NM_010217]
West
A_51_P124748 NM_009368 0.45 7.08E-04 Mus musculus transforming growth factor, beta 3 
(Tgfb3), mRNA [NM_009368]
West
A_51_P212754 NM_009369 11.76 1.54E-03 Mus musculus transforming growth factor, beta 
induced (Tgfbi), mRNA [NM_009369]
Iacobuzio-Donahue
A_51_P472292 NM_008048 65.79 6.80E-09 Mus musculus insulin-like growth factor binding 
protein 7 (Igfbp7), mRNA [NM_008048]
Iacobuzio-Donahue
A_51_P110301 NM_009778 4.59 3.95E-05 Mus musculus complement component 3 (C3), 
mRNA [NM_009778]
Iacobuzio-Donahue
A_51_P218774 NM_026418 2.74 9.21E-04 Mus musculus regulator of G-protein signalling 10 
(Rgs10), mRNA [NM_026418]
Iacobuzio-Donahue
A_51_P224843 NM_021278 2.84 2.24E-03 Mus musculus thymosin, beta 4, X chromosome 
(Tmsb4x), mRNA [NM_021278]
Iacobuzio-DonahueBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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A_51_P111210 NM_133786 1.10 1.45E-01 Mus musculus SMC4 structural maintenance of 
chromosomes 4-like 1 (yeast) (Smc4l1), mRNA 
[NM_133786]
Iacobuzio-Donahue
A_52_P101852 NM_009242 27.25 1.90E-07 Mus musculus secreted acidic cysteine rich 
glycoprotein (Sparc), mRNA [NM_009242]
Iacobuzio-Donahue
A_51_P431087 NM_009242 67.11 1.96E-08 Mus musculus secreted acidic cysteine rich 
glycoprotein (Sparc), mRNA [NM_009242]
Iacobuzio-Donahue
A_51_P452876 NM_021515 7.46 3.48E-06 Mus musculus adenylate kinase 1 (Ak1), mRNA 
[NM_021515]
Iacobuzio-Donahue
A_51_P149562 NM_009686 6.13 1.52E-04 Mus musculus amyloid beta (A4) precursor 
protein-binding, family B, member 2 (Apbb2), 
mRNA [NM_009686]
Iacobuzio-Donahue
A_52_P49250 NM_010152 0.86 4.40E-03 Mus musculus v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian) (Erbb2), 
transcript variant 2, mRNA [NM_010152]
Iacobuzio-Donahue
A_51_P216179 NM_010152 0.54 3.14E-03 Mus musculus v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian) (Erbb2), 
transcript variant 2, mRNA [NM_010152]
Iacobuzio-Donahue
A_51_P341736 NM_008610 2.74 1.93E-04 Mus musculus matrix metalloproteinase 2 
(Mmp2), mRNA [NM_008610]
Wang, Singer
A_51_P258529 NM_008885 15.77 3.73E-05 Mus musculus peripheral myelin protein (Pmp22), 
mRNA [NM_008885]
Kunz-Schughart
A_51_P213359 NM_008216 23.70 1.46E-07 Mus musculus hyaluronan synthase 2 (Has2), 
mRNA [NM_008216]
Li
A_52_P582374 NM_178825 0.04 5.59E-03 Mus musculus epithelial stromal interaction 1 
(breast) (Epsti1), transcript variant b, mRNA 
[NM_178825]
Gudjonsson
A_51_P376050 NM_029495 0.03 2.78E-03 Mus musculus epithelial stromal interaction 1 
(breast) (Epsti1), transcript variant a, mRNA 
[NM_029495]
Gudjonsson
A_51_P127681 NM_013885 3.62 1.28E-07 Mus musculus chloride intracellular channel 4 
(mitochondrial) (Clic4), mRNA [NM_013885]
Suh, Ronnov-Jessen
A_51_P392687 NM_011701 25.000 5.47E-04 Mus musculus vimentin (Vim), mRNA 
[NM_011701]
A_52_P56471 NM_007912 4.35 8.57E-06 Mus musculus epidermal growth factor receptor 
(Egfr), transcript variant 2, mRNA [NM_007912]
A_51_P392242 NM_007912 4.17 1.10E-05 Mus musculus epidermal growth factor receptor 
(Egfr), transcript variant 2, mRNA [NM_007912]
A_52_P674338 NM_207655 7.14 1.90E-03 Mus musculus epidermal growth factor receptor 
(Egfr), transcript variant 1, mRNA [NM_207655]
A_52_P106259 NM_207655 11.56 2.06E-05 Mus musculus epidermal growth factor receptor 
(Egfr), transcript variant 1, mRNA [NM_207655]
A_51_P414813 NM_010153 0.61 3.13E-03 Mus musculus v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 3 (avian) (Erbb3), mRNA 
[NM_010153]
A_51_P342050 NM_010153 0.58 3.28E-02 Mus musculus v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 3 (avian) (Erbb3), mRNA 
[NM_010153]
A_52_P420504 NM_007392 17.18 7.97E-05 Mus musculus actin, alpha 2, smooth muscle, 
aorta (Acta2), mRNA [NM_007392]
A_52_P210078 NM_007392 101.94 6.74E-05 Mus musculus actin, alpha 2, smooth muscle, 
aorta (Acta2), mRNA [NM_007392]
A_51_P103396 NM_016879 0.260 2.69E-04 Mus musculus keratin complex 2, basic, gene 18 
(Krt2-18), mRNA [NM_016879]
A_51_P356642 NM_008471 5.550 7.53E-06 Mus musculus keratin complex 1, acidic, gene 19 
(Krt1-19), mRNA [NM_008471]
A_51_P482128 NM_008469 2.760 3.01E-04 Mus musculus keratin complex 1, acidic, gene 15 
(Krt1-15), mRNA [NM_008469]
A_51_P118225 NM_028078 0.028 7.55E-04 Mus musculus junction adhesion molecule 4 
(Jam4), mRNA [NM_028078]
A_51_P358354 NM_023277 30.030 2.21E-06 Mus musculus junction adhesion molecule 3 
(Jam3), mRNA [NM_023277]
A_52_P374846 NM_023844 19.120 9.97E-04 Mus musculus junction adhesion molecule 2 
(Jam2), mRNA [NM_023844]
A_51_P418375 NM_023844 10.256 8.90E-04 Mus musculus junction adhesion molecule 2 
(Jam2), mRNA [NM_023844]
A_52_P93974 NM_021359 0.316 1.46E-02 Mus musculus integrin beta 6 (Itgb6), mRNA 
[NM_021359]
A_52_P459521 NM_001005607 0.261 3.06E-05 Mus musculus integrin beta 4 (Itgb4), transcript 
variant 3, mRNA [NM_001005607]
A_51_P382970 NM_133721 25.125 3.19E-02 Mus musculus integrin alpha 9 (Itga9), mRNA 
[NM_133721]
A_52_P413034 NM_008398 2.985 2.73E-02 Mus musculus integrin alpha 7 (Itga7), mRNA 
[NM_008398]
A_51_P181671 NM_008398 3.401 4.71E-03 Mus musculus integrin alpha 7 (Itga7), mRNA 
[NM_008398]
A_52_P364140 NM_010577 30.030 1.76E-06 Mus musculus integrin alpha 5 (fibronectin 
receptor alpha) (Itga5), mRNA [NM_010577]
A_52_P223495 NM_010576 0.304 4.71E-02 Mus musculus integrin alpha 4 (Itga4), mRNA 
[NM_010576]
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A_51_P515056 NM_013565 0.316 9.78E-05 Mus musculus integrin alpha 3 (Itga3), mRNA 
[NM_013565]
A_51_P230405 NM_013565 0.260 5.62E-05 Mus musculus integrin alpha 3 (Itga3), mRNA 
[NM_013565]
A_52_P612019 NM_008396 3.300 3.55E-02 Mus musculus integrin alpha 2 (Itga2), mRNA 
[NM_008396]
aAverage fold difference is the ratio (n = 3, p value cutoff > .05) compares the expression levels of MAM-1 RNA normalized to Universal Mouse 
RNA to Bam1a RNA normalized to Universal Mouse RNA. RNA from MAM-1 or Bam1a was labeled in red color (cy5), universal RNA is labeled in 
green (cy3). Three independent RNA preparations per condition were analyzed on three separate chips and averaged; a confidence cutoff of >0.95 
was used for the raw values of red/green before normalization. The fold change (**MAM-1 or Bam1a/**Universal Mouse) = Normalized ratio 
value(cy5/cy3). P-values are for the comparisons between the MAM-1 and Bam1a. The references associated with specific genes are indicated in the 
text of the manuscript.
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To determine the long term impact of these effects on cell
growth and survival we treated MAM-1 co-cultures with
Iressa for longer periods of time.
Treatment of MAM-1 with Iressa generates a fibrotic 
response in vitro
When treated for an extended period of time with Iressa,
the morphology of the MAM-1 co-culture recapitulated a
fibrotic response such that tumor cell nests and islands
gradually eroded away and stromal cells increased in den-
sity forming multi-cell layer nests (Fig. 6A). Our primary
observation was that the morphology and cellularity of
the co-cultures was dramatically altered. Within 24 h of
treatment with 1 µM Iressa, there was a decrease in the cel-
lularity of tumor cell nests and an increase in the cellular-
ity and density of α-SMA reactive material associated with
the stromal cell layers (Fig. 6B). Decreased cellularity of
the tumor cell nests is accompanied by significant tumor
cell rounding and apoptosis as evidenced by nuclear frag-
mentation shown with DAPI staining (Fig 7A) as well as
positivity for Annexin V binding and cleaved caspase 3
(not shown). In addition to apoptosis, when probed for
PCNA, there was a marked reduction in tumor cell PCNA
and robust staining of PCNA in the stromal cells (Fig. 7A).
Basic flow cytometric evaluation of these cultures demon-
strated a 44% reduction in the tumor cell population
within 24 h of treatment with 1 µM Iressa and a >3-fold
increase in the stromal cell population when compared to
control cultures (not shown). When we evaluated the
PCNA, phospho-p44/42 MAPK and phospho-MEK1/2
levels in the ErbB-2 positive and ErbB-2 negative subpop-
ulations we observed a 62%, 54% and 27% reductions in
tumor cell PCNA, phospho-p44/42 MAPK and phospho-
MEK1/2, respective (Fig 7B). Interestingly, the larger sub-
population of tumor cells in these treated co-cultures were
approximately 2-fold less responsive to Iressa in terms of
PCNA and phospho-p44/42 MAPK levels attesting to the
transient resistance afforded to cells likely in G2/M (not
shown). In contrast to ErbB-2 positive tumor cells, ErbB-2
negative stromal cells had a robust increase in all of these
proliferation markers following treatment with Iressa.
PCNA levels increased by 205%, phospho-p44/42 MAPK
increased 219% and phospho-pMEK1/2 increased by
279%. These data are in agreement with our qualitative
observations that used immunofluorescence to document
the relative density of the tumor and stroma cell popula-
tions in the MAM-1 co-cultures (Fig. 6B). The resilience of
the stromal cell population is not limited to EGFR antag-
onists. We have also observed that while both the tumor
and stroma cells express comparable levels of the TRAIL
death receptor DR5, only the tumor cells are sensitive to
TRAIL-mediated apoptosis (data not shown). Thus, target-
ing the stroma to effectively "sterilize" the microenviron-
ment and inhibit tumor growth and progression presents
a major challenge.
Gene expression analysis reveals a signature of the fibrotic 
response
To generate a better understanding of the global response
of MAM-1 to Iressa, we compared the gene expression
profiles of MAM-1 co-cultures treated for 24 h with fresh
media containing diluent or 1 µM Iressa. We observed a
strong upregulation of inflammatory genes involved in
the fibrotic response, consistent with the morphology of
the treated MAM-1 co-cultures (Fig. 6A). Interestingly,
none of the genes that were modulated by Iressa in Bam1a
cells [6] were altered in MAM-1. We observed 2.5- to 6-
fold increases in the expression of genes associated with
inflammatory, fibrotic, pathological processes that are
observed in a variety of diseases [34-37]. Most notably, we
observed increases in inflammatory genes, (C9,  CCR7,
TNFRS25, IL1F9, CCL22, TLR8, KLRA23, CLEC4N, CD22),
cell adhesion genes, (COL4A3,  SIGLEC5,  LGALS12,
CLDN5) growth factor signaling and transcription genes,
(FGF22,  CTGF,  WNT8A,  POU4F3,  HEY1) proliferation
and differentiation (CCNB3,  MYB,  TFF1,  PROX1) and
proteolysis genes (GZMK, TLL2, ADAM5, SERPINA1D).
Conclusion
Our data demonstrate the utility of the MAM-1 co-culture
model in understanding the impact of the tumor microen-
vironment on the differential responses of invasive breast
cancers and tumor associated myofibroblasts to chemo-
therapeutic agents and therapeutic modalities. Our dataBMC Cancer 2008, 8:119 http://www.biomedcentral.com/1471-2407/8/119
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Effect of Iressa on phosphorylation of p44/42 MAPK by (A) Immunofluorescence and phosphorylation of p44/42 MAPK and  MEK1/2 by (B) flow cytometry in MAM-1 co-cultures Figure 5
Effect of Iressa on phosphorylation of p44/42 MAPK by (A) Immunofluorescence and phosphorylation of p44/
42 MAPK and MEK1/2 by (B) flow cytometry in MAM-1 co-cultures. MAM-1 were subcultured on coverslips or in 6-
well plates and grown to ~95% confluence and then treated by replacing the conditioned media with fresh media that con-
tained diluent (.001% DMSO, Control) or Iressa for 2 hours prior to fixing and evaluation as described in the methods. A. 
Immunofluorescent photomicrographs were taken with the indicated objectives of cells that were double labeled for phospho-
p44/42 MAPK (Thr202/Tyr204) in green (FITC) and α-SMA in red (TRITC) and counterstained with DAPI (blue) to define the 
nuclei. B. Dose-response for phosphorylation of p44/42 MAPK and MEK1/2 in MAM-1 co-cultures by flow cytometry. MAM-1 
were treated as described above and dual-labeled for ErbB-2 and the indicated phospho-specific antigen. Bars represent Mean 
channel fluorescent values for pp44/42 MAPK (Thr202/Tyr204) (Blue Bars) or pMEK1/2 (Ser217/221) (Red Bars) in ErbB2+ 
(Solid Bars) and ErbB2-(Shaded Bars) subpopulations.
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Differential Effects of Iressa on growth and morphology Figure 6
Differential Effects of Iressa on growth and morphology. MAM-1 co-cultures were treated for 24–48 h by replacing 
conditioned media with fresh media in the absence (Control) or presence of 1 µM Iressa. A. Phase contrast photomicrographs 
of MAM-1 co-cultures following treatment with 1 µM Iressa were taken using a 10× objective. Tumor cell nests (T) decrease in 
cellularity over time and stromal cells (S) thicken and increase in cellularity. By 48 h tumor cell nests erode, cells flatten, and 
show evidence of apoptosis while stromal cells develop into multi-cell layer nests recapitulating the morphology of a fibrotic 
response in vitro. B. Immunofluorescence of MAM-1 that were dual-labeled with HER2/neu-TRITC and α-SMA-FITC to iden-
tify the tumor (red) and stromal (green) subpopulations, respectively. Photographs taken under low power (10×) show 
decreased cellularity of HER2+ nests (red) and increased cellularity and density in the α-SMA+ stroma (green). These shifts in 
the cellularity of the separate subpopulations are emphasized by the nuclear counterstain with DAPI (blue). Under higher mag-
nification (40×) HER2+ nests of tumor cells (red) have decreased in cellularity and flattened into a monolayer while the cellular-
ity and α-SMA reactivity has increased in the stromal elements surrounding the tumor cells generating the thickened 
appearance that is associated with fibrosis. Note in particular the membrane accentuation of HER2/neu in the tumor cells 
treated with Iressa and the dense bundles of a-SMA reactive fibers in Iressa treated stroma.
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Effect of Iressa on (A) PCNA activity and (B) Signal transduction in the tumor and stromal cell populations of MAM-1 co-cul- tures Figure 7
Effect of Iressa on (A) PCNA activity and (B) Signal transduction in the tumor and stromal cell populations of 
MAM-1 co-cultures. A. MAM-1 co-cultures were treated for 24 h with fresh media in the absence (Control) or presence of 
1 µM Iressa then fixed and stained with PC10-TRITC to detect PCNA reactivity (red) and counterstained with DAPI to identify 
the nuclei (blue) Photomicrographs were taken with the 100× objective under oil immersion. The PCNA index of control 
tumor cells is >95% and <12% in the Iressa treated tumor cells. In the stroma adjacent to the Iressa treated tumor nest, PCNA 
index is >95%. Note the presence of apoptotic cells in DAPI stained tumor cells treated with Iressa (arrow). B. Differential 
effect of Iressa on PCNA, phospho-p44/42 MAPK (Thr202/Tyr204) and phospho-MEK1/2 (Ser217/221) in the ErbB-2 Negative 
(Stromal) and ErbB-2 Positive (Tumor) populations in MAM-1 treated for 24 h with 1 µM Iressa. Samples were dual-labeled for 
ErbB-2 and the indicated antigen and evaluated by dual-color flow cytometry. Bars represent the Mean Channel Fluorescent 
Values for phospho-p44/42 MAPK (Blue Bars), phospho-MEK1/2 (Red Bars) or PCNA (Black Bars). Following Iressa treatment, 
the ErbB-2 positive population decreased by 44% and the α-SMA positive population increased 3-fold in these MAM-1 co-cul-
tures.
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suggest that Iressa preferentially targets signal transduc-
tion from the tumor cell HER2/neu leading to tumor cell
death and a fibro-proliferative response in the stroma. In
this co-culture model tumor cells retain their intrinsic sen-
sitivity to Iressa and the tumor associated myofibroblasts
of the stroma demonstrate intrinsic resistance to Iressa.
Understanding the tumor regulatory properties of this
microenvironment before, during and after treatment will
be critical in determining the most appropriate treatment
modality to prevent progression and recurrence.
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